logo-loader
RNS
viewHikma Pharmaceuticals Plc

Director/PDMR Shareholding

/**/ .s{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.s{}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.as{font-family:"Arial","sans-serif"}p.au{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}p.av{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.aq{font-family:"Arial","sans-serif";color:black}span.ap{font-family:"Arial","sans-serif"; color:black}p.aw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt; text-align: center; text-decoration: underline}p.ax{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt; text-decoration: underline} table.ay{border:solid windowtext 1.0pt}tr.ah{page-break-inside:avoid}td.aj{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm}p.az{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 6.0pt; margin-left: 5.65pt; margin-right: 0cm; margin-top: 6.0pt}span.al{font-family: "Arial","sans-serif"}td.ai{width:432.6pt;border:solid windowtext 1.0pt; padding:0cm 0cm 0cm 0cm}tr.ac{page-break-inside:avoid;height:30.95pt}td.af{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm; height:30.95pt}p.ba{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:5.65pt;line-height:normal}td.ae{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:30.95pt} td.ad{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:30.95pt}td.ab{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm}td.aa{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm}tr.w{page-break-inside:avoid;height:37.4pt}td.z{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm; height:37.4pt}td.y{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:37.4pt}td.x{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:37.4pt}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt} /**/
RNS Number : 2519W
Hikma Pharmaceuticals Plc
15 April 2019
 

 

Hikma Pharmaceuticals PLC - EIP Vesting

LONDON, 15 April 2019: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 13 April 2017 under the 2014 Executive Incentive Plan ("EIP") Element B which was completed on 15 April 2019.  

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from vesting of the conditional awards on
15 April 2019 under the 2014 EIP Element B.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 60,973

d)

Aggregated information

N/A

e)

Date of the transaction

15 April 2019

f)

Place of the transaction

London Stock Exchange (XLON)

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from vesting of the conditional awards on
15 April 2019 under the 2014 EIP Element B.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 33,005

d)

Aggregated information

N/A

e)

Date of the transaction

15 April 2019

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from vesting of the nil-cost option on
15 April 2019 under the 2014 EIP Element B.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 22,241

d)

Aggregated information

N/A

e)

Date of the transaction

15 April 2019

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

 

 

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from vesting of the conditional awards on
15 April 2019 under the 2014 EIP Element B.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 17,825

d)

Aggregated information

N/A

e)

Date of the transaction

15 April 2019

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

 

 

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from vesting of the conditional awards on
15 April 2019 under the 2014 EIP Element B.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 27,578

d)

Aggregated information

N/A

e)

Date of the transaction

15 April 2019

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from vesting of the conditional awards on
15 April 2019 under the 2014 EIP Element B.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 26,174

d)

Aggregated information

N/A

e)

Date of the transaction

15 April 2019

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHBUGDSDDBBGCU

Quick facts: Hikma Pharmaceuticals Plc

Price: 1889.5

Market: AIM
Market Cap: £4.58 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE